[HTML][HTML] DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment
X Guo, H Feng, L Cai, J Zheng, Y Li - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Along with social development and lifestyle changes, the number of overweight and obese
patients worldwide is rising annually. Obesity is a chronic metabolic disease with complex …
patients worldwide is rising annually. Obesity is a chronic metabolic disease with complex …
Polygonatum cyrtonema saponin supplementation ameliorated DSS-induced intestinal barrier injury via targeting the PI3K/AKT/mTOR-mediated autophagy/microbiota …
Autophagy is pivotal for the management of intestinal homeostasis, modulation of intestinal
immunity response and anti-microbial protection. Previous studies have documented the …
immunity response and anti-microbial protection. Previous studies have documented the …
A sensitive fluorescence assay of serum dipeptidyl peptidase IV activity to predict the suitability of its inhibitors in patients with type 2 diabetes mellitus
J Zhang, YD Zhu, CQ Li, YM Fan, H Huo… - … of Pharmaceutical and …, 2024 - Elsevier
DPP-IV inhibitors, which are close to the natural hypoglycemic pathway of human
physiology and have few side effects, have been extensively employed in the management …
physiology and have few side effects, have been extensively employed in the management …